Lead Product(s): THOR-707
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Deal Size: $2,500.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 23, 2020
Under the terms and conditions of the deal, Synthorx’ lead candidate THOR-707 is being tested against multiple tumour types, and will also be tested in combination with Sanofi’s own cancer drugs.